AAPL   393.00 (+2.43%)
MSFT   213.76 (+0.04%)
GOOGL   1,560.32 (+1.38%)
NVDA   417.89 (-0.31%)
CGC   18.00 (+3.33%)
MU   50.71 (+0.02%)
TSLA   1,577.87 (+2.15%)
AMD   56.01 (+0.23%)
ACB   12.43 (+3.41%)
F   6.19 (+1.48%)
GILD   78.02 (+2.23%)
DIS   119.51 (+0.14%)
BAC   24.28 (+1.08%)
BA   181.62 (+1.78%)
AAPL   393.00 (+2.43%)
MSFT   213.76 (+0.04%)
GOOGL   1,560.32 (+1.38%)
NVDA   417.89 (-0.31%)
CGC   18.00 (+3.33%)
MU   50.71 (+0.02%)
TSLA   1,577.87 (+2.15%)
AMD   56.01 (+0.23%)
ACB   12.43 (+3.41%)
F   6.19 (+1.48%)
GILD   78.02 (+2.23%)
DIS   119.51 (+0.14%)
BAC   24.28 (+1.08%)
BA   181.62 (+1.78%)
AAPL   393.00 (+2.43%)
MSFT   213.76 (+0.04%)
GOOGL   1,560.32 (+1.38%)
NVDA   417.89 (-0.31%)
CGC   18.00 (+3.33%)
MU   50.71 (+0.02%)
TSLA   1,577.87 (+2.15%)
AMD   56.01 (+0.23%)
ACB   12.43 (+3.41%)
F   6.19 (+1.48%)
GILD   78.02 (+2.23%)
DIS   119.51 (+0.14%)
BAC   24.28 (+1.08%)
BA   181.62 (+1.78%)
AAPL   393.00 (+2.43%)
MSFT   213.76 (+0.04%)
GOOGL   1,560.32 (+1.38%)
NVDA   417.89 (-0.31%)
CGC   18.00 (+3.33%)
MU   50.71 (+0.02%)
TSLA   1,577.87 (+2.15%)
AMD   56.01 (+0.23%)
ACB   12.43 (+3.41%)
F   6.19 (+1.48%)
GILD   78.02 (+2.23%)
DIS   119.51 (+0.14%)
BAC   24.28 (+1.08%)
BA   181.62 (+1.78%)
Log in

NASDAQ:TLSATiziana Life Sciences Stock Price, Forecast & News

$9.05
+1.22 (+15.58 %)
(As of 07/13/2020 02:03 PM ET)
Add
Compare
Today's Range
$7.97
Now: $9.05
$9.06
50-Day Range
$5.15
MA: $6.18
$7.41
52-Week Range
$1.54
Now: $9.05
$8.56
Volume8,340 shs
Average Volume178,471 shs
Market Capitalization$232.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLSA
CUSIPN/A
CIKN/A
Phone44-20-7495-2379

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.21) per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$232.49 million
Next Earnings Date9/16/2020 (Estimated)
OptionableNot Optionable

Receive TLSA News and Ratings via Email

Sign-up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

Tiziana Life Sciences (NASDAQ:TLSA) Frequently Asked Questions

How has Tiziana Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

Tiziana Life Sciences' stock was trading at $3.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TLSA stock has increased by 129.1% and is now trading at $9.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tiziana Life Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tiziana Life Sciences.

When is Tiziana Life Sciences' next earnings date?

Tiziana Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, September 16th 2020. View our earnings forecast for Tiziana Life Sciences.

What price target have analysts set for TLSA?

2 equities research analysts have issued 1-year target prices for Tiziana Life Sciences' shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Tiziana Life Sciences' share price to reach $22.50 in the next year. This suggests a possible upside of 148.6% from the stock's current price. View analysts' price targets for Tiziana Life Sciences.

Has Tiziana Life Sciences been receiving favorable news coverage?

Media headlines about TLSA stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tiziana Life Sciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Tiziana Life Sciences.

Who are some of Tiziana Life Sciences' key competitors?

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Crispr Therapeutics (CRSP), Micron Technology (MU), Vaxart (VXRT), Agile Therapeutics (AGRX), NVIDIA (NVDA), Occidental Petroleum (OXY), VBI Vaccines (VBIV) and vTv Therapeutics (VTVT).

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the following people:
  • Mr. Gabriele Marco Antonio Cerrone, Founder & Exec. Chairman (Age 46)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 60)
  • Dr. Andrea Brancale Ph.D., Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder
  • Mr. Andrew Westwell Ph.D., Scientific Founder

When did Tiziana Life Sciences IPO?

(TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA."

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tiziana Life Sciences' stock price today?

One share of TLSA stock can currently be purchased for approximately $9.05.

How big of a company is Tiziana Life Sciences?

Tiziana Life Sciences has a market capitalization of $232.49 million. The company earns $-9,320,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Tiziana Life Sciences' official website?

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7495-2379 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.